Navigation Links
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Date:4/28/2009

endent prostate cancer, may represent the first product in a new class of active cellular immunotherapies (ACI). PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer.

Conference Call Scheduled for Today at 5:30 pm ET

Dendreon will host a conference call today at 5:30 pm ET. To access the live call, dial 1-877-675-4753 (domestic) or 719-325-4864 (international). The call also will be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 (domestic) or 719-457-0820 (international); the conference ID number is 6483399. The replay will be available from 8:00 p.m. ET on April 28, 2009 until midnight on April 29, 2009. In addition, the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, v
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  CVS Health (NYSE: ... into new clinical affiliations with Rush University Medical ... and Tucson Medical Center in Tucson, ... Arizona Connected Care. These affiliations will help enhance ... patients. Through these clinical affiliations, CVS Health will ...
(Date:3/31/2015)... , March 31, 2015  Oxis International, Inc. ... therapy development and commercialization, announced today Oxis CEO ... trading of Oxis common shares on the Euronext exchange. ... under the symbol OXIS.   Oxis Chairman ... continues to move forward with its strategies launched in ...
(Date:3/31/2015)... , March 31, 2015 Biorasi ... announced a strategic partnership with Medidata , ... clinical research in life sciences. Offering therapeutic expertise ... has deployed Medidata,s electronic data capture (EDC), management ... Phase I through IV global clinical trial business. ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4
... 6 Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Bisaro, Watson,s president and chief executive officer, will provide ... the Credit Suisse 18th Annual Healthcare Conference on Wednesday, ... , This presentation will be webcast live and can ...
... , CHARLESTON, S.C., Nov. 6 The ... in South Carolina and Georgia throughout the week of ... uninsured and financially-struggling patients access information on programs that ... the nation,s unemployment rate now hitting 10.2 percent, the ...
Cached Medicine Technology:Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3
(Date:3/31/2015)... VA (PRWEB) March 31, 2015 ... takes place from April 1-7, the Mesothelioma Applied ... its new prevention program, to complement its existing ... , “As part of the Meso Foundation’s ... extinguish fears of diseases related to asbestos, including ...
(Date:3/31/2015)... 2015 Simeon Boyd, UC Davis professor ... million, five-year grant from the National Institute of Dental ... and scientists from more than 10 centers in the ... Bulgaria, Germany, Hungary, Italy and the United Kingdom, to ... of the skull in infants. , The researchers are ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Students, teachers, ... requirement for education in a drastically different way as ... which learning and training content is being delivered and ... impacted by technology in an unprecedented way with education ... Wemel Cumavoo, co-founder and CEO, My Mobile University ...
(Date:3/31/2015)... Dr. St. Ledger recently returned from yet ... Education. Here, he participated in the Worn Dentition Workshop: ... greater predictability in cases of severely worn teeth, as well ... and the correlation to GERD and Sleep Apnea. ... Education. After the workshop he attended, he mentored for ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Researchers ... between mice and humans: how human livers heal. ... which activates liver regeneration. Normally, mouse PPARa is ... form, allowing mice to quickly regenerate damaged livers. ... factor 21 (FGF21) can boost the regenerative effects ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 2Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 3Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:The dentists at Upper Montclair Dental Associates are happy to announce exciting new happenings at their practice. 2Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 2Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 3Health News:UC Davis Study Finds Protein May Improve Liver Regeneration 4
... from more emotional and behavioral difficulties when compared to ... the most when a parent is deployed overseas, according ... that having a parent deployed for a longer period ... struggled with emotional problems were important factors associated with ...
... , NEW ORLEANS and SUNNYVALE, Calif., Dec. ... interim results from a Phase I/II study showing safety and ... (NHL) treated with its HDAC inhibitor PCI-24781 as a single ... Annual Meeting being held in New Orleans, LA (Abstract # ...
... growth factor, researchers say , SUNDAY, Dec. 6 (HealthDay ... main tumor to other parts of the body is controlled ... a promising target for new drugs to prevent metastatic breast ... TGFb (transforming growth factor beta) regulates normal cell growth and ...
... NEW ORLEANS, Dec. 6 Sickle cell disease, a condition ... of the most common genetic blood disorders affecting millions of ... presented today at the 51st Annual Meeting of the American ... that the H1N1 pandemic presents for children with this blood ...
... ... Greater VA Healthcare System in West Los Angeles, will once again create a holiday party. ... and their families. , ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of the community, in cooperation ...
... 5 , What: Cuts for a Cause ... fight against cancer and other terminal illnesses affecting children. All proceeds ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, ... Falls Church for all guests. Hoa Lai, a DJ known for ...
Cached Medicine News:Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... advanced glass technologies and designs, the ... field views of the mid and ... lens will provide image quality previously ... of examination for more detailed and ...
Medicine Products: